Company: VCYT
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001384101-25-000060
Chunk: 16

Company: VERACYTE, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
 — 1,271 — — 1,271 Issuance of common stock under ESPP80 — 1,697 — — 1,697 Tax portion of vested restricted stock units— — (3,832)— — (3,832)Stock-based compensation expense (employee)— — 7,728 — — 7,728 Stock-based compensation expense (ESPP)— — 291 — — 291 Net loss— — — (1,864)— (1,864)Other comprehensive loss— — — — (4,889)(4,889)Balance at March 31, 202476,425 $76 $1,617,465 $(469,985)$(28,907)$1,118,649 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

VERACYTE, INC.  

Condensed Consolidated Statements of Cash Flows 

(Unaudited) 

(In thousands)

 Three Months Ended March 31, 20252024Operating activities  Net income (loss)$7,047 $(1,864)Adjustments to reconcile net income (loss) to net cash provided by operating activities:Depreciation and amortization5,362 5,590 Loss on disposal of property, plant and equipment— 30 Stock-based compensation10,958 8,019 Deferred income taxes15 (120)Noncash lease expense904 1,139 Revaluation of acquisition-related contingent consideration(1,954)5 Effect of foreign currency on operations(1,585)637 Impairment loss— 429 Changes in operating assets and liabilities:Accounts receivable(7,053)(6,459)Supplies and inventory(2,298)(2,303)Prepaid expenses and other current assets(2,928)(2,738)Other assets(760)259 Operating lease liabilities(577)(1,053)Accounts payable7,120 (1,544)Accrued liabilities and deferred revenue(8,889)(8,993)Net cash provided by (used in) operating activities5,362 (8,966)Investing activitiesAcquisition of C2i, net of cash acquired— 5,012 Purchase of short-term investments(49,999)— Purchases of property